Leaps by Bayer has led the seed round for Edifice Health, which spun out of Stanford University and also attracted Ahren Innovation Capital.
Edifice Health, a US-based immunology technology developer spun out of Stanford University’s 1,000 Immunomes Project, has collected $12m in a seed round backed by patient capital fund Ahren Innovation Capital.
Leaps by Bayer, the corporate venturing arm of chemicals and pharmaceutical producer Bayer, led the round, which also featured Human Longevity and Performance Impact Venture Fund, Longevity Incubator Fund, Summer Venture Capital, Carlyle Global Advisors, M4 Capital and Better Food Ventures.
Pharmaceutical firm Taisho Pharmaceutical and Paladin Capital Group, Vertical Venture Partners, Ataraxia Capital Partners, Shanda Grab Ventures and Alafi Capital filled out the line-up.
Edifice hopes to tackle chronic diseases of aging. The money will accelerate company growth and support recruitment activities.
Leaps by Bayer’s Naveen Krishnan and Paladin Group’s Paul Conley will join Edifice’s board together with David Furman, founder of Edifice, leader of the Stanford Project and associate professor of applied artificial intelligence in systems and computational immunology of aging at the Buck Institute for Research on Aging, and Santosh Padki.